digest
Short Summary
Main recommendation: GLP-1 receptor agonists, specifically liraglutide and semaglutide, are the two FDA-approved GLP-1 medications for long-term weight management, and the video reviews the major trials supporting their use. Semaglutide produced greater weight loss than liraglutide in the STEP 8 trial, and continued use is needed to maintain the loss.
Key Points
- GLP-1 (Glucagon-Like Peptide 1) is an incretin hormone released by intestinal L cells after eating, with receptors throughout the brain, gut, and pancreas.
- Of five FDA-approved weight-management medications as of 2021, liraglutide and semaglutide are the two GLP-1 receptor agonists with specific long-term weight management indications; orlistat works in the gut by reducing fat digestion and absorption.
- Both drugs were first approved as glucose-lowering treatments for type 2 diabetes, but trials in people without diabetes confirmed weight loss.
- Stopping treatment leads to weight regain: in the STEP 4 trial, participants who switched to placebo regained weight while those continuing semaglutide kept losing.
Details Worth Noting
- Concrete instructions: The transcript gives no step-by-step patient instructions, but it specifies the trial dosing: liraglutide 3.0 mg subcutaneously once daily (SCALE trial) and semaglutide 2.4 mg subcutaneously once weekly (STEP 1 trial), both paired with lifestyle modification counseling.
- SCALE trial (liraglutide vs. placebo, about 3,700 patients, 56 weeks): liraglutide lost a mean 8.0% (8.4 kg) of body weight versus 2.6% (2.8 kg) with placebo.
- STEP 1 trial (semaglutide vs. placebo, just under 2,000 patients, 68 weeks): semaglutide lost a mean 14.9% versus 2.4% with placebo, an estimated treatment difference of 12.4%.
- In STEP 1, 51% of semaglutide participants lost 15% or more of their weight, compared with 5% on placebo; 86% on semaglutide reached at least 5% loss versus 32% on placebo.
- STEP 8 trial (338 participants, 68 weeks): semaglutide produced a 15.8% mean weight change versus 6.4% with liraglutide, a treatment difference of 9.4%.
- Eligibility in these trials was a BMI of at least 30, or at least 27 with a weight-related condition such as dyslipidemia, hypertension, or another weight-related coexisting condition.
Bottom Line
Semaglutide and liraglutide are the approved GLP-1 options for long-term weight management, with semaglutide showing the larger effect in head-to-head data, but the weight loss depends on staying on the medication. The video presents trial results and does not provide professional medical advice.
